- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05139862
Neurocardiac Predictors of Treatment Response to rTMS in Depression (NCP)
January 18, 2022 updated by: Fidel Vila-Rodriguez, University of British Columbia
Neuro-cardiac Predictors of Treatment Response to rTMS in Depression: A Mechanistic Study Using Interleaved TMS-fMRI
Heartbeat is controlled by the brain and is regular but flexible to change in response to environmental and internal stimuli.
This feature is known as heart rate variability (HRV).
Major depressive disorder (MDD) has been associated with diminished HRV and this is a reflection of abnormal brain function caused by MDD.
Repetitive transcranial magnetic stimulation (rTMS) is a treatment that stimulates specific areas of the brain.
The goal of this study is to test the hypothesis that rTMS induces changes in connectivity between the area of the brain stimulated with rTMS and deeper areas in the brain associated to heart rate regulation.
110 patients with TRD will be recruited and will undergo a concurrent TMS-fMRI session before receiving a course of iTBS to the L-DLPFC for 30 sessions at 120% rMT.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
110
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Quincy Beck, B.Sc.
- Phone Number: 604-822-7308
- Email: quincy.beck@ubc.ca
Study Contact Backup
- Name: Fidel Vila-Rodriguez, M.D., Ph.D.
- Phone Number: 604-827-1361
- Email: ninet.lab@ubc.ca
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 2A1
- Non-Invasive Neurostimulation Therapies (NINET) Laboratory, UBC Department of Psychiatry
-
Principal Investigator:
- Fidel Vila-Rodriguez, M.D., Ph.D.
-
Contact:
- Quincy Beck, B.Sc.
- Phone Number: 604-822-7308
- Email: quincy.beck@ubc.ca
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patients will be included if they:
- are female or male;
- are outpatients;
- are voluntary and competent to consent to treatment;
- have a DSM 5 diagnosis of MDD, single or recurrent confirmed by Mini-International Neuropsychiatric Interview (MINI) version 6.0;
- are between the ages of 18 and 65 years;
- have failed to achieve a clinical response to an adequate dose of an antidepressant based on an Antidepressant Treatment History Form (ATHF) score of > 3 in the current episode OR have been unable to tolerate at least two separate trials of antidepressants at less than the minimum adequate dose and/or duration (ATHF 1 or 2);
- A score ≥ 18 on the Hamilton Depression Rating Scale (HDRS-17 item);
- Have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening;
- Able to adhere to the treatment schedule;
- pass the TMS and MRI adult safety screening questionnaires.
Exclusion Criteria:
Patients are excluded if they:
- have a history of substance use within the last 3 months;
- have a concomitant major unstable medical illness;
- have active suicidal intent;
- are pregnant;
- have a lifetime (MINI) diagnosis of any psychotic or bipolar disorder;
- have a MINI anxiety disorder or personality disorder assessed by a study investigator to be primary and causing greater impairment than MDD;
- have ever failed a course of ECT;
- have previously received rTMS;
- have any significant neurological disorder, any history of seizure (except those therapeutically induced by ECT), significant head trauma with loss of consciousness for > 5 min;
- have any intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed;
- if participating in psychotherapy, must have been in stable treatment for at least 3 months prior to study entry, with no anticipated change in the frequency of therapeutic sessions, or focus of therapeutic sessions over the duration of the study;
- have a clinically significant laboratory abnormality, in the opinion of the one of the principal investigators;
- are currently taking lorazepam greater than 2 mg daily (or equivalent) or any dose of an anticonvulsant, due to the potential to limit rTMS efficacy;
- have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview);
- have failed more than three adequate trials (ATHF > 3) of medication in the current episode.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active iTBS
Active intermittent theta-burst stimulation (iTBS) rTMS session on the left dorsolateral prefrontal cortex (L-DLPFC)
|
This study utilizes intermittent theta burst stimulation (iTBS) to the left DLPFC.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Depressive Symptoms using HDRS-17 Scale at Week 10
Time Frame: Baseline and Week 10
|
The 17-item Hamilton Depression Rating Scale (HRSD-17) will be used as the primary outcome measure as well as the tool to establish severity cut off for eligibility (Hamilton, 1960).
The scoring ranges from 0-52, with higher scores indicating more severe depression symptoms.
|
Baseline and Week 10
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Anxiety Symptoms using HAM-A Scale at Week 10
Time Frame: Baseline and Week 10
|
The 14-item Hamilton Anxiety Rating Scale (HAM-A) will be used as a secondary outcome measure in this study.
The scoring of this assessment ranges from 0-56, with higher scores indicating more severe anxiety symptoms.
|
Baseline and Week 10
|
Change from Baseline in Depressive Symptoms using QIDS-16 Scale at Week 10
Time Frame: Baseline and Week 10
|
The self-rated 16-item Quick Inventory of Depressive Symptoms (QIDS-16) will be used as a secondary outcome measure in this study.
The scoring of this assessment ranges from 0-27, with higher scores indicating more severe depression symptoms.
|
Baseline and Week 10
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Fidel Vila-Rodriguez, M.D., Ph.D., Department of Psychiatry, UBC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
February 1, 2022
Primary Completion (Anticipated)
December 1, 2024
Study Completion (Anticipated)
December 1, 2024
Study Registration Dates
First Submitted
November 17, 2021
First Submitted That Met QC Criteria
November 17, 2021
First Posted (Actual)
December 1, 2021
Study Record Updates
Last Update Posted (Actual)
February 2, 2022
Last Update Submitted That Met QC Criteria
January 18, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H19-00648
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Lawson Health Research InstituteTerminated
Clinical Trials on Repetitive Transcranial Magnetic Stimulation
-
State University of New York - Upstate Medical...RecruitingHeadache | Brain Concussion | Mild Traumatic Brain Injury | Post-Concussion SymptomsUnited States
-
Xuzhou Central HospitalThe Affiliated Hospital of Xuzhou Medical UniversityNot yet recruitingFunctional Magnetic Resonance Imaging | Executive Function Disorder
-
Al-Azhar UniversityCompleted
-
Guangzhou Psychiatric HospitalCompletedCognitive Impairment | Bipolar Disorder | RelapseChina
-
Fatih Sultan Mehmet Training and Research HospitalCompletedFailed Back Surgery Syndrome
-
Veterans Medical Research FoundationUnited States Department of DefenseCompletedHeadache | Gulf War SyndromeUnited States
-
Yi YangRecruitingTranscranial Magnetic StimulationChina
-
Yi YangRecruitingTranscranial Magnetic StimulationChina
-
First Affiliated Hospital of Zhejiang UniversityCompletedBipolar DisorderChina
-
Izmir Katip Celebi UniversityCompletedPost-stroke Shoulder PainTurkey